Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    facet.materialart.
    Unknown
    German Medical Science GMS Publishing House; Düsseldorf
    In:  61. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) im Rahmen der Neurowoche 2010; 20100921-20100925; Mannheim; DOCP1727 /20100916/
    Publication Date: 2010-09-17
    Keywords: ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Abstract: In den letzten Jahren hat sich der Workshop "Bildverarbeitung für die Medizin" durch erfolgreiche Veranstaltungen etabliert. Ziel ist auch 2010 wieder die Darstellung aktueller Forschungsergebnisse und die Vertiefung der Gespräche zwischen Wissenschaftlern, Industrie und Anwendern. Die Beiträge dieses Bandes - einige in englischer Sprache - behandeln alle Bereiche der medizinischen Bildverarbeitung, insbesondere Bildgebung, CAD, Segmentierung, Bildanalyse, Visualisierung und Animation, Roboter und Manipulatoren, Chirurgische Simulatoren, Diagnose, Therapieplanung sowie deren klinische Anwendungen.
    Type of Publication: Book chapter
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
  • 4
    Publication Date: 2008-12-10
    Description: The prevalence of fibromyalgia syndrome (FMS) of 1-2% in the general population associated with high disease-related costs and the conflicting data on treatment effectiveness had led to the development of evidence-based guidelines designed to provide patients and physicians guidance in selecting among the alternatives. Until now no evidence-based interdisciplinary (including patients) guideline for the management of FMS was available in Europe. Therefore a guideline for the management of fibromyalgia syndrome (FMS) was developed by 13 German medical and psychological associations and two patient self-help organisations. The task was coordinated by two German scientific umbrella organisations, the Association of the Scientific Medical Societies in Germany AWMF and the German Interdisciplinary Association of Pain Therapy DIVS. A systematic search of the literature including all controlled studies, systematic reviews and meta-analyses of pharmacological and non-pharmacological treatments of FMS was performed in the Cochrane Library (1993-12/2006), Medline (1980-12/2006), PsychInfo (1966-12/2006) and Scopus (1980-12/ 2006). Levels of evidence were assigned according to the classification system of the Oxford-Centre for Evidence Based Medicine. Grading of the strengths of recommendations was done according to the German program for disease management guidelines. Standardized procedures were used to reach a consensus on recommendations. The guideline was reviewed and finally approved by the boards of the societies involved and published online by the AWMF on april 25, 2008: http://www.uni-duesseldorf.de/AWMF/ll/041-004.htm. A short version of the guideline for patients is available as well: http://www.uni-duesseldorf.de/AWMF/ll/041-004p.htm. The following procedures in the management of FMS were strongly recommended: information on diagnosis and therapeutic options and patient-centered communication, aerobic exercise, cognitive and operant behavioural therapy, multicomponent treatment and amitriptyline. Based on expert opinion, a stepwise FMS-management was proposed. Step 1 comprises confirming the diagnosis and patient education and treatment of physical or mental comorbidities or aerobic exercise or cognitive behavioural therapy or amitriptyline. Step 2 includes multicomponent treatment. Step 3 comprises no further treatment or self-management (aerobic exercise, stress management) and/or booster multicomponent therapy and/or pharmacological therapy (duloxetine or fluoxetine or paroxetine or pregabalin or tramadol/aminoacetophen) and/or psychotherapy (hypnotherapy or written emotional disclosure) and/or physical therapy (balneotherapy or whole body heat therapy) and/or complementary therapies (homoeopathy or vegetarian diet). The choice of treatment options should be based on informed decision-making and respect of the patients' preferences.
    Description: Die Prävalenz des Fibromyalgiesyndroms (FMS) in der allgemeinen Bevölkerung beträgt 1-2%. Aufgrund der mit FMS verbundenen hohen Krankheitskosten und den widersprüchlichen Daten zur Wirksamkeit einzelner Behandlungsformen wurden evidenzbasierte Leitlinien entwickelt, um Ärzten und Patienten einen Entscheidungshilfe zu geben. Bisher war in Europa keine interdisziplinäre evidenzbasierte Leitlinie unter Einschluss von Patienten zum FMS verfügbar. Deswegen wurde von 13 deutschen medizinischen und psychologischen Fachgesellschaften und zwei Patientenselbsthilfeorganisationen eine Leitlinie zu Therapie des FMS entwickelt. Die Durchführung wurde von der Deutschen Interdisziplinären Vereinigung für Schmerztherapie DIVS und der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften in Deutschland AWMF koordiniert. Eine systematische Literatursuche aller kontrollierte Studien, systematischer Reviews und Metaanalysen wurde über die Datenbanken Cochrane Library (1993-12/2006), Medline (1980-12/2006), PsychInfo (1966-12/2006) und Scopus (1980-12/ 2006) durchgeführt. Für die Vergabe von Evidenzklassen wurde das System des Oxford-Centre for Evidence Based Medicine verwendet. Für die Vergabe von Empfehlungsgraden wurde die Empfehlungsgraduierung der nationalen Versorgungsleitlinien verwendet. Die Erstellung der Empfehlungen erfolgte in einem mehrstufigen nominalen Gruppenprozess, welcher von einer Vertreterin der AWMF moderiert wurde. Die Leitlinie wurde von den Vorständen der beteiligten Fachgesellschaften begutachtet und genehmigt. Die wissenschaftliche Lang- und Kurzversion der Leitlinie wurde am 25. April 2008 von der AWMF ins Internet gestellt: http://www.uni-duesseldorf.de/AWMF/ll/041-004.htm. Eine Kurzversion für Patienten ist ebenfalls verfügbar: http://www.uni-duesseldorf.de/AWMF/ll/041-004p.htm. Folgende Therapieverfahren erhielten eine starke Empfehlung: Informationen über Diagnose und Behandlungsmöglichkeiten, patienten-zentrierte Kommunikation, aerobes Ausdauertraining, kognitive und operante Verhaltenstherapie, multimodale Therapie und Amitriptylin. Basierend auf Expertenmeinung wurde eine stufenweise Behandlung des FMS empfohlen: Stufe 1 beinhaltet Diagnosebestätigung und Patientenschulung und/oder Behandlung körperlicher und psychischer Komorbiditäten oder aerobes Ausdauertraining oder kognitive und operante Verhaltenstherapie oder Amitriptylin. Stufe 2 beinhaltet multimodale Therapie. Stufe 3 umfasst die folgenden Behandlungsoptionen: keine weitere Behandlung oder Selbstmanagement (aerobes Ausdauertraining, Stressmanagement) und/oder multimodale Auffrischungstherapie und/oder phamakologische Therapie (Duloxetin oder Fluoxetin oder Pregabalin oder Tramadol/Paracetamol) und/oder psychotherapeutische Verfahren (Hypnotherapie oder therapeutisches Schreiben) oder physikalische Therapie (Balneotherapie oder Ganzkörperwärmetherapie) und/oder komplementäre Therapien (Homöopathie oder vegetarische Kost). Die Wahl der Behandlungsoptionen soll auf gemeinsame Entscheidungsfindung und unter Berücksichtigung der Patientenpräferenzen durchgeführt werden.
    Keywords: FIBROMYALGIA/* ; FIBROMYALGIA/drug therapy ; FIBROMYALGIA/epidemiology ; FIBROMYALGIA/ therapy ; FIBROMYALGIA/* rehabilitation ; FIBROMYALGIA/ psychology ; PRACTICE GUIDELINES AS TOPIC ; EVIDENCE-BASED MEDICINE ; PATIENT EDUCATION AS TOPIC ; DELIVERY OF HEALTH CARE ; EUROPE ; PATIENT CARE TEAM ; QUALITY ASSURANCE, HEALTH CARE ; HUMANS ; FIBROMYALGIE/* ; FIBROMYALGIE/Arzneimitteltherapie ; FIBROMYALGIE/Epidemiologie ; FIBROMYALGIE ; FIBROMYALGIE/* ; FIBROMYALGIE ; KLINISCHE LEITLINIEN ; GUTACHTENBASIERTE MEDIZIN ; PATIENTENSCHULUNG ; GESUNDHEITSVERSORGUNG ; EUROPA ; KRANKENBEHANDLUNGSTEAM ; QUALITÄTSSICHERUNG IM GESUNDHEITSWESEN ; MENSCH ; fibromyalgia syndrome ; systematic review ; guideline ; management ; Fibromyalgiesyndrom ; systematische Übersicht ; Leitlinie ; Behandlung ; ddc: 610
    Language: English
    Type: article
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    facet.materialart.
    Unknown
    German Medical Science GMS Publishing House; Düsseldorf
    In:  InVeST 2015: International Veterinary Simulation in Teaching Conference; 20150914-20150916; Hannover; DOC15invest10 /20150910/
    Publication Date: 2015-09-11
    Keywords: ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    facet.materialart.
    Unknown
    German Medical Science GMS Publishing House; Düsseldorf
    In:  66. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC); 20150607-20150610; Karlsruhe; DOCDI.09.07 /20150602/
    Publication Date: 2015-06-03
    Keywords: meningioma ; supraorbital approach ; adverse events ; ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 7
    facet.materialart.
    Unknown
    German Medical Science GMS Publishing House; Düsseldorf
    In:  64. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC); 20130526-20130529; Düsseldorf; DOCDI.11.05 /20130521/
    Publication Date: 2013-05-22
    Keywords: subarachnoid hemorrhage ; DCI ; vasospams ; ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 8
    facet.materialart.
    Unknown
    German Medical Science GMS Publishing House; Düsseldorf
    In:  57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN); 20120912-20120915; Erlangen; DOC12dgnnPP2.1 /20120911/
    Publication Date: 2012-09-12
    Keywords: ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 9
    Keywords: RECEPTOR ; CELLS ; EXPRESSION ; IN-VITRO ; SURVIVAL ; ENDOTHELIAL GROWTH-FACTOR ; Germany ; IN-VIVO ; MODEL ; MODELS ; PATHWAY ; PATHWAYS ; VITRO ; GENERATION ; VOLUME ; DEATH ; DISEASE ; DISEASES ; DRUG ; DIFFERENTIATION ; LIGAND ; MECHANISM ; RAT ; CELL-SURVIVAL ; CELL-DEATH ; LONG-TERM SURVIVAL ; TRANSIENT GLOBAL-ISCHEMIA ; STEM-CELLS ; CENTRAL-NERVOUS-SYSTEM ; COLONY-STIMULATING FACTOR ; STROKE ; signaling ; ADULT ; FOCAL CEREBRAL-ISCHEMIA ; NEURONS ; cell survival ; CEREBRAL-ISCHEMIA ; NEURAL STEM-CELLS ; cell death ; progenitor ; FUNCTIONAL RECOVERY ; MATURE ; RECOVERY ; NEURONAL DIFFERENTIATION ; HIPPOCAMPAL-NEURONS ; FACTOR G-CSF ; INFARCT ; NEWLY GENERATED NEURONS ; RAT DENTATE GYRUS
    Abstract: G-CSF is a potent hematopoietic factor that enhances survival and drives differentiation of myeloid lineage cells, resulting in the generation of neutrophilic granulocytes. Here, we show that G-CSF passes the intact blood-brain barrier and reduces infarct volume in 2 different rat models of acute stroke. G-CSF displays strong antiapoptotic activity in mature neurons and activates multiple cell survival pathways. Both G-CSF and its receptor are widely expressed by neurons in the CNS, and their expression is induced by ischemia, which suggests an autocrine protective signaling mechanism. Surprisingly, the G-CSF receptor was also expressed by adult neural stem cells, and G-CSF induced neuronal differentiation in vitro. G-CSF markedly improved long-term behavioral outcome after cortical ischemia, while stimulating neural progenitor response in vivo, providing a link to functional recovery. Thus, G-CSF is an endogenous ligand in the CNS that has a dual activity beneficial both in counteracting acute neuronal degeneration and contributing to long-term plasticity after cerebral ischemia. We therefore propose G-CSF as a potential new drug for stroke and neurodegenerative diseases
    Type of Publication: Journal article published
    PubMed ID: 16007267
    Signatur Availability
    BibTip Others were also interested in ...
  • 10
    Keywords: 3-KINASE, AKT, APOPTOSIS, ARTERY, BARRIER, Bcl-2, BLOOD, BLOOD-BRAIN, BLOOD-BRAIN-BARRIER, BLOOD-FLO
    Abstract: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic cytokine responsible for the proliferation, differentiation, and maturation of cells of the myeloid lineage, which was cloned more than 20 years ago. Here we uncovered a novel function of GM-CSF in the central nervous system (CNS). We identified the GM-CSF alpha-receptor as an upregulated gene in a screen for ischemia-induced genes in the cortex. This receptor is broadly expressed on neurons throughout the brain together with its ligand and induced by ischemic insults. In primary cortical neurons and human neuroblastoma cells, GM-CSF counteracts programmed cell death and induces BCL-2 and BCL-XI expression in a dose- and time-dependent manner. Of the signaling pathways studied, GMCSF most prominently induced the PI3K-Akt pathway, and inhibition of Akt strongly decreased antiapoptotic activity. Intravenously given GM-CSF passes the blood-brain barrier, and decreases infarct damage in two different experimental stroke models (middle cerebral artery occlusion (MCAO), and combined common carotid/distal MCA occlusion) concomitant with induction of BCL-XI expression. Thus, GM-CSF acts as a neuroprotective protein in the CNS. This finding is remarkably reminiscent of the recently discovered functionality of two other hematopoietic factors, erythropoietin and granulocyte colony-stimulating factor in the CNS. The identification of a third hematopoietic factor acting as a neurotrophic factor in the CNS suggests a common principle in the functional evolution of these factors. Clinically, GM-CSF now broadens the repertoire of hematopoietic factors available as novel drug candidates for stroke and neurodegenerative diseases
    Type of Publication: Journal article published
    PubMed ID: 17457367
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...